Literature DB >> 32133538

Analysis of synovial biomarkers with a multiplex protein microarray in patients with PJI undergoing revision arthroplasty of the hip or knee joint.

F S Fröschen1, S Schell2,3, F A Schildberg2, A Klausing2,4, H Kohlhof2, S Gravius2,5, T M Randau2.   

Abstract

INTRODUCTION: Diagnosing a (low-grade) periprosthetic joint infection (PJI) after hip or knee arthroplasty remains a diagnostic challenge. The aim of this study was to evaluate the utility of using a novel multiplex protein microarray system for synovial biomarkers in determining PJI in patients undergoing revision knee or hip arthroplasty.
MATERIALS AND METHODS: The individual synovial fluid levels of 12 cytokines (IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-17, GM-CSF, TNF-α, and INF-γ) were analysed with a novel multiplex protein microarray system in 32 patients undergoing revision hip (n = 22) or knee (n = 10) arthroplasty. Cases were classified into septic and aseptic groups on basis of pre- and interoperative findings: [PJI (n = 14) vs. non-PJI (n = 18)]. Receiver operator characteristic (ROC) curves were calculated to assess the discriminatory strength of the individual parameters. A multiple regression model was used to determine the utility of using a combination of the tested cytokines to determine the infection status.
RESULTS: The levels of all of the evaluated cytokines were significantly elevated in the PJI-group. Best sensitivity and specificity were found for IL-6, followed by IL-1b, IL-10, and IL-17. The multiple regression models revealed a combination of IL-2, IL-4, IL-5, IL6, lL-12, and GM-CSF to be associated with the best sensitivity (100%) and specificity (88.9%) for a cut-off value of 0.41, with a likelihood ratio of 9.0.
CONCLUSION: Analysis of individual synovial fluid cytokine levels showed both high sensitivity and high specificity in diagnosing PJI. A combined model using several cytokines showed even higher sensitivity and specificity in diagnosing PJI and could thus be a useful predictive tool to determine the probability of PJI in patients with a painful prosthesis. LEVEL OF EVIDENCE: Diagnostic IV.

Entities:  

Keywords:  Cytokine; Periprosthetic joint infection; Revision arthroplasty; Synovial fluid

Mesh:

Substances:

Year:  2020        PMID: 32133538     DOI: 10.1007/s00402-020-03388-5

Source DB:  PubMed          Journal:  Arch Orthop Trauma Surg        ISSN: 0936-8051            Impact factor:   3.067


  6 in total

1.  Osteoporosis in patients with rheumatoid arthritis is associated with serum immune regulatory cellular factors.

Authors:  Jianjun Qiu; Chunde Lu; Lei Zhang; Xu Zhou; Hanlin Zou
Journal:  Clin Rheumatol       Date:  2022-06-07       Impact factor: 3.650

2.  Tissue-level cytokines in a rodent model of chronic implant-associated infection.

Authors:  Nicole Prince; Julia A Penatzer; Taylor L Shackleford; Elizabeth K Stewart; Matthew J Dietz; Jonathan W Boyd
Journal:  J Orthop Res       Date:  2020-12-15       Impact factor: 3.102

3.  Interleukin-18 and -10 may be associated with lymph node metastasis in breast cancer.

Authors:  Teng Ma; Meng Kong
Journal:  Oncol Lett       Date:  2021-02-03       Impact factor: 2.967

4.  Combination of Synovial Fluid IL-4 and Polymorphonuclear Cell Percentage Improves the Diagnostic Accuracy of Chronic Periprosthetic Joint Infection.

Authors:  Jiaxing Huang; Jiawei Wang; Leilei Qin; Bo Zhu; Wei Huang; Ning Hu
Journal:  Front Surg       Date:  2022-03-09

5.  Synovial Complement Factors in Patients with Periprosthetic Joint Infection after Undergoing Revision Arthroplasty of the Hip or Knee Joint.

Authors:  Frank Sebastian Fröschen; Sophia Schell; Matthias Dominik Wimmer; Gunnar Thorben Rembert Hischebeth; Hendrik Kohlhof; Sascha Gravius; Thomas Martin Randau
Journal:  Diagnostics (Basel)       Date:  2021-03-04

6.  Failure Analysis in Multiple TKA Revisions-Periprosthetic Infections Remain Surgeons' Nemesis.

Authors:  Stephanie Kirschbaum; Sarah Erhart; Carsten Perka; Robert Hube; Kathi Thiele
Journal:  J Clin Med       Date:  2022-01-13       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.